ATAD3A and hepatocellular carcinoma: This was confirmed by treating hepatoma cells with CoCl2 and/or the miR-210-5P inhibitor, which showed that hypoxia-induced downregulation of ATAD3A was abrogated by blocking miR-210-5P (Fig. 4m-o).